DFG / Sonderforschungsbereich (SFB)

Next-generation printed semiconductors: Atomic-level engineering via surface molecular chemistry (ChemPrint) Oct. 1, 2025 - June 30, 2029 ChemPrint: Next-generation printed semiconductors: Atomic-level engineering via molecular surface chemistry (SFB 1719) Oct. 1, 2025 - June 30, 2029 Direct comparison of structure and performance of vacuum- and solution-processed photovoltaic devices (SFB 1719 F04) ChemPrint: Next-generation printed semiconductors: Atomic-level engineering via molecular surface chemistry (SFB 1719) Oct. 1, 2025 - June 30, 2029 Controlling deposit site and morphology via covalent and non-covalent interactions (SFB 1719 C01) ChemPrint: Next-generation printed semiconductors: Atomic-level engineering via molecular surface chemistry (SFB 1719) Oct. 1, 2025 - June 30, 2029 Central Task of the Collaborative Research Center - Coordination (SFB 1719 Z) ChemPrint: Next-generation printed semiconductors: Atomic-level engineering via molecular surface chemistry (SFB 1719) Oct. 1, 2025 - June 30, 2029 Excited-state phenomena: Unraveling structure-property relationships across dimensions (SFB 1719 M02) ChemPrint: Next-generation printed semiconductors: Atomic-level engineering via molecular surface chemistry (SFB 1719) Oct. 1, 2025 - June 30, 2029 InterFEARence – Assessing feared movements in people with chronic back pain with EmpkinS sensor technology (SFB 1483 - D07) Empatho-Kinaesthetic Sensor Technology (SFB 1483 EmpkinS) Oct. 1, 2024 - July 31, 2027 Impact of wild-type intestinal microbiome on impaired immune regulation during acute graft-versus-host-disease (SFB 1160 B10) SFB 1160: Immunpathologie aufgrund eingeschränkter Immunreaktionen (IMPATH) July 1, 2023 - June 30, 2027 Die Rolle von epithelialem Zelltod für die Wiederherstellung der Darmbarriere im Zuge der Abheilung von Darmentzündung (C05) (SFB 1181 C05) SFB 1181: Schaltstellen zur Auflösung von Entzündung July 1, 2015 - June 30, 2027 CD83-basierte Immunmodulation bei Entzündungen der Augenoberfläche am Bespiel des trockenen Auges (B03) (SFB 1607 B03) SFB 1607: Neue immunmodulierende und anti(lymph)angiogene Therapien für altersassoziierte, zur Erblindung führende Augenerkrankungen Jan. 1, 2024 - Jan. 1, 2027